+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Short Bowel Syndrome Market - Global Forecast to 2030- Product Image
Short Bowel Syndrome Market - Global Forecast to 2030- Product Image
Sale

Short Bowel Syndrome Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011692
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Short Bowel Syndrome Market grew from USD 966.42 million in 2024 to USD 1.16 billion in 2025. It is expected to continue growing at a CAGR of 19.35%, reaching USD 2.79 billion by 2030.

Short Bowel Syndrome (SBS) arises following extensive resection of the small intestine, resulting in malabsorption, nutritional deficiencies, and complex clinical management challenges. Patients often face chronic dehydration, weight loss, and dependence on parenteral nutrition to meet basic metabolic demands. Advances in pharmacotherapy-including recombinant peptides and growth hormone therapies-alongside surgical innovations such as bowel lengthening procedures, have begun to shift patient outcomes. At the same time, evolving care delivery models now integrate home-based nutritional support and telemetry for real-time monitoring. Given the diversity of patient populations, ranging from adult onset cases to pediatric presentations, stakeholders require a thorough understanding of emerging therapeutic pathways and care algorithms. This executive summary introduces key market drivers, regulatory influences, and clinical breakthroughs that collectively define the current state of SBS management. By establishing this foundation, readers will gain clarity on the strategic intersections of treatment modalities, patient care settings, and evolving technology platforms.

Transformative Shifts Reshaping Diagnosis and Treatment Paradigms

Recent years have witnessed transformative shifts reshaping SBS diagnosis and treatment paradigms. First, the introduction of GLP-2 analogs such as teduglutide has redefined intestinal adaptation, reducing parenteral dependency and improving nutrient absorption. Concurrently, growth hormone replacement strategies have shown incremental benefits in promoting mucosal growth. On the surgical front, innovations in bowel lengthening procedures, including serial transverse enteroplasty, and minimally invasive techniques like robotic-assisted laparoscopic surgery, are enabling improved functional outcomes. In parallel, precision nutrition plans leverage tailored parenteral formulas and enteral feeds designed to optimize macronutrient uptake and microbiome balance. Regulatory agencies have responded by streamlining approval pathways for orphan indications, accelerating clinical studies in gene and stem cell therapies targeting intestinal regeneration. Patient-centric models now emphasize home care solutions, integrating caregiver training with digital health platforms to monitor hydration status, nutrient delivery, and symptom progression. Finally, strategic partnerships between pharmaceutical developers and medical device manufacturers are fostering integrated therapy kits that combine pharmacologic agents with advanced enteral delivery systems. Collectively, these converging trends mark a fundamental shift toward holistic, multidisciplinary SBS management.

Assessing the Cumulative Impact of United States Tariffs in 2025

The imposition of updated United States tariff schedules in 2025 is poised to influence the SBS supply chain and cost structure. Increased duties on active pharmaceutical ingredients and specialized medical-grade components may elevate procurement costs for enteral pumps, infusion sets, and biotechnologically derived peptides. Moreover, tariffs on raw materials used in parenteral nutrition formulations could necessitate strategic sourcing from alternative regions or domestic production initiatives. As a result, manufacturers may pursue near-shoring of API synthesis or negotiate volume-based agreements with suppliers to mitigate price pressures. Healthcare providers, in turn, will need to renegotiate reimbursement contracts to reflect adjusted input costs, potentially impacting patient access and out-of-pocket expenses. In response, stakeholders are already evaluating supply chain resilience measures-such as dual-sourcing agreements and inventory buffer strategies-to ensure continuity of critical therapies. Additionally, collaborative advocacy with regulatory bodies aims to secure tariff exemptions for life-sustaining SBS treatments. By proactively addressing these macroeconomic headwinds, industry participants can preserve treatment affordability while maintaining high-quality care delivery across both inpatient and home settings.

Comprehensive Segmentation Insights Driving Market Dynamics

The SBS market delineates across multiple dimensions that together drive strategic decision-making. Based on type, the market differentiates adult presentations from pediatric cases, each requiring distinct growth and nutritional protocols. Treatment segmentation encompasses medical therapy-spanning dietary management through specialized formulas and pharmacologic interventions-and surgical therapy, which includes bowel lengthening procedures alongside intestinal transplant options. Drug segmentation bifurcates into GLP-2 analogs, notably teduglutide, and growth hormone therapies such as replacement regimens. Patient care contexts range from home-based models that feature caregiver assistance paired with home parenteral nutrition to hospital settings offering inpatient nutritional support. End-user segmentation extends across clinics, home healthcare services, hospitals, and specialty centers. Technological segmentation contrasts non-surgical treatments like innovative drug delivery systems with surgical innovations including laparoscopic and robotic procedures. Complication management focuses on dehydration, intestinal failure, and malabsorption, while nutrition type analysis compares enteral nutrition against parenteral solutions, the latter offering both standard and tailored formulations. Associated condition segmentation addresses chronic management strategies featuring diet modification and long-term supplementation as well as extended recovery initiatives such as intestinal rehabilitation programs. Finally, innovations and research track ongoing clinical studies and emerging therapies, from gene therapy trials to stem cell-based regenerative approaches.

Regional Variations Highlighted Across Key Global Markets

Regional analysis uncovers distinct trends across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, robust reimbursement frameworks and established specialty centers drive rapid adoption of advanced pharmacotherapies and home parenteral nutrition models. Key regulatory initiatives in the United States continue to facilitate orphan drug designations, bolstering investment in SBS-specific biologics. Moving east, Europe, Middle East & Africa demonstrate increasing harmonization of regulatory standards, enabling cross-border clinical collaboration and expedited access to novel therapies. Market access strategies in this region leverage public-private partnerships to fund patient support programs, while emerging telehealth platforms expand remote monitoring capabilities. Meanwhile, Asia-Pacific markets exhibit rising SBS incidence linked to improved surgical survival rates, prompting governments to subsidize high-cost interventions. Local manufacturers are scaling production of generic parenteral formulations to meet growing demand, and joint ventures with multinational pharma companies accelerate technology transfer. These regional nuances underscore the importance of tailored market entry strategies and localized care delivery models.

Competitive Landscape and Key Company Strategies

Competitive dynamics in the SBS landscape reflect a diverse array of innovative and established players. Companies such as 9 Meters Biopharma, Inc. and Adocia SAS are pioneering novel GLP-2 analog formulations, while Ardelyx Inc. and AstraZeneca PLC invest heavily in peptide-based therapies. Emmaus Life Sciences, Inc. collaborates with Merck KGaA on targeted growth hormone delivery systems, and global nutrition leader Nestlé S.A. partners with Novartis International AG to enhance parenteral formula portfolios. OPKO Health, Inc. and Oxthera AB explore alternative hormone analogs, as Pfizer Inc. expands its intestinal rehabilitation pipeline. PhaseBio Pharmaceuticals Inc. and Sancilio and Company, Inc. focus on next-generation enteral delivery devices, complemented by Swedish Orphan Biovitrum AB’s orphan drug expertise. Major pharmaceutical groups, including Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd., leverage scale to drive therapy access, while VectivBio AG, Viatris Inc., and Zealand Pharma A/S emphasize regenerative and gene therapy research. Collaboration among these organizations-through licensing agreements, co-development partnerships, and joint ventures-has accelerated the translation of research into clinical practice, intensifying competition and expanding treatment options for patients worldwide.

Actionable Recommendations to Propel Industry Leadership

To capitalize on emerging opportunities and address evolving market pressures, industry leaders should pursue several actionable strategies. First, forging strategic partnerships with academic centers and technology firms can accelerate the development of gene and stem cell therapies, enabling access to new regenerative approaches. Second, integrating digital health solutions-such as remote monitoring platforms and AI-driven nutritional algorithms-will enhance patient adherence and enable real-time intervention. Third, diversifying supply chains through dual sourcing and near-shoring arrangements can mitigate the impact of tariff changes and reduce dependency on single suppliers. Fourth, engaging proactively with regulatory agencies to secure expedited pathways and tariff exemptions for life-sustaining therapies will safeguard patient access and stabilize pricing dynamics. Fifth, expanding patient support infrastructure by collaborating with home healthcare providers and specialty centers can improve quality of life and reduce inpatient burden. Finally, investing in real-world evidence generation through patient registries and outcome studies will strengthen reimbursement negotiations and reinforce therapy value propositions. By aligning these initiatives with long-term R&D roadmaps and commercial objectives, organizations can reinforce their competitive positioning and deliver sustained value to stakeholders.

Conclusion Emphasizing Future Directions for Short Bowel Care

In summary, the Short Bowel Syndrome market stands at an inflection point, driven by pharmacologic breakthroughs, surgical innovations, and evolving care delivery models. The convergence of GLP-2 analog therapies, growth hormone applications, and precision nutrition strategies is reshaping clinical standards, while digital health integration and home-based support redefine patient engagement. Tariff adjustments in 2025 introduce new supply chain considerations, underscoring the need for agile procurement and regulatory advocacy. Comprehensive segmentation analysis highlights the multifaceted nature of this market, encompassing diverse patient populations, treatment modalities, and end-user channels across global regions. A dynamic competitive landscape featuring both specialized biotech firms and established pharmaceutical conglomerates points to robust collaboration and intensified innovation. Moving forward, stakeholders must prioritize strategic partnerships, supply chain resilience, and data-driven market access tactics to translate scientific progress into improved patient outcomes. This executive summary offers a roadmap for navigating the complex SBS environment, equipping decision-makers with insights to inform R&D investment, commercial strategy, and policy engagement.

Market Segmentation & Coverage

This research report categorizes the Short Bowel Syndrome Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Adult Short Bowel Syndrome
  • Pediatric Short Bowel Syndrome
  • Medical Therapy
    • Dietary Management
    • Medications
  • Surgical Therapy
    • Bowel Lengthening Procedures
    • Intestinal Transplant
  • GLP-2 Analog
    • Teduglutide
  • Growth Hormone
    • Growth Hormone Replacement Therapy
  • Home Care
    • Caregiver Assistance
    • Home Parenteral Nutrition
  • Hospital Care
    • Inpatient Nutritional Support
  • Clinics
  • Home Healthcare
  • Hospitals
  • Specialty Centers
  • Non-Surgical Treatments
    • Innovative Drug Delivery Systems
  • Surgical Innovations
    • Laparoscopic Surgery
    • Robotic Surgical Procedures
  • Dehydration
  • Intestinal Failure
  • Malabsorption
  • Enteral Nutrition
  • Parenteral Nutrition
    • Standard Parenteral Nutrition
    • Tailored Nutritional Formulas
  • Chronic Management
    • Diet Modification
    • Long-Term Supplementation
  • Extended Recovery
    • Intestinal Rehabilitation Programs
  • Clinical Studies
    • Ongoing Trials
  • Emerging Therapies
    • Gene Therapy
    • Stem Cell Therapy

This research report categorizes the Short Bowel Syndrome Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Short Bowel Syndrome Market to delves into recent significant developments and analyze trends in each of the following companies:

  • 9 Meters Biopharma, Inc.
  • Adocia SAS
  • Ardelyx Inc.
  • AstraZeneca PLC
  • Emmaus Life Sciences, Inc.
  • Merck KGaA
  • Nestlé S.A.
  • Novartis International AG
  • OPKO Health, Inc.
  • Oxthera AB
  • Pfizer Inc.
  • PhaseBio Pharmaceuticals Inc.
  • Sancilio and Company, Inc.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • VectivBio AG
  • Viatris Inc.
  • Zealand Pharma A/S

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Short Bowel Syndrome Market, by Type
8.1. Introduction
8.2. Adult Short Bowel Syndrome
8.3. Pediatric Short Bowel Syndrome
9. Short Bowel Syndrome Market, by Treatment
9.1. Introduction
9.2. Medical Therapy
9.2.1. Dietary Management
9.2.2. Medications
9.3. Surgical Therapy
9.3.1. Bowel Lengthening Procedures
9.3.2. Intestinal Transplant
10. Short Bowel Syndrome Market, by Drugs
10.1. Introduction
10.2. GLP-2 Analog
10.2.1. Teduglutide
10.3. Growth Hormone
10.3.1. Growth Hormone Replacement Therapy
11. Short Bowel Syndrome Market, by Patient Care
11.1. Introduction
11.2. Home Care
11.2.1. Caregiver Assistance
11.2.2. Home Parenteral Nutrition
11.3. Hospital Care
11.3.1. Inpatient Nutritional Support
12. Short Bowel Syndrome Market, by End-User
12.1. Introduction
12.2. Clinics
12.3. Home Healthcare
12.4. Hospitals
12.5. Specialty Centers
13. Short Bowel Syndrome Market, by Technology
13.1. Introduction
13.2. Non-Surgical Treatments
13.2.1. Innovative Drug Delivery Systems
13.3. Surgical Innovations
13.3.1. Laparoscopic Surgery
13.3.2. Robotic Surgical Procedures
14. Short Bowel Syndrome Market, by Complication Management
14.1. Introduction
14.2. Dehydration
14.3. Intestinal Failure
14.4. Malabsorption
15. Short Bowel Syndrome Market, by Nutrition Type
15.1. Introduction
15.2. Enteral Nutrition
15.3. Parenteral Nutrition
15.3.1. Standard Parenteral Nutrition
15.3.2. Tailored Nutritional Formulas
16. Short Bowel Syndrome Market, by Associated Conditions
16.1. Introduction
16.2. Chronic Management
16.2.1. Diet Modification
16.2.2. Long-Term Supplementation
16.3. Extended Recovery
16.3.1. Intestinal Rehabilitation Programs
17. Short Bowel Syndrome Market, by Innovations and Research
17.1. Introduction
17.2. Clinical Studies
17.2.1. Ongoing Trials
17.3. Emerging Therapies
17.3.1. Gene Therapy
17.3.2. Stem Cell Therapy
18. Americas Short Bowel Syndrome Market
18.1. Introduction
18.2. Argentina
18.3. Brazil
18.4. Canada
18.5. Mexico
18.6. United States
19. Asia-Pacific Short Bowel Syndrome Market
19.1. Introduction
19.2. Australia
19.3. China
19.4. India
19.5. Indonesia
19.6. Japan
19.7. Malaysia
19.8. Philippines
19.9. Singapore
19.10. South Korea
19.11. Taiwan
19.12. Thailand
19.13. Vietnam
20. Europe, Middle East & Africa Short Bowel Syndrome Market
20.1. Introduction
20.2. Denmark
20.3. Egypt
20.4. Finland
20.5. France
20.6. Germany
20.7. Israel
20.8. Italy
20.9. Netherlands
20.10. Nigeria
20.11. Norway
20.12. Poland
20.13. Qatar
20.14. Russia
20.15. Saudi Arabia
20.16. South Africa
20.17. Spain
20.18. Sweden
20.19. Switzerland
20.20. Turkey
20.21. United Arab Emirates
20.22. United Kingdom
21. Competitive Landscape
21.1. Market Share Analysis, 2024
21.2. FPNV Positioning Matrix, 2024
21.3. Competitive Analysis
21.3.1. 9 Meters Biopharma, Inc.
21.3.2. Adocia SAS
21.3.3. Ardelyx Inc.
21.3.4. AstraZeneca PLC
21.3.5. Emmaus Life Sciences, Inc.
21.3.6. Merck KGaA
21.3.7. Nestlé S.A.
21.3.8. Novartis International AG
21.3.9. OPKO Health, Inc.
21.3.10. Oxthera AB
21.3.11. Pfizer Inc.
21.3.12. PhaseBio Pharmaceuticals Inc.
21.3.13. Sancilio and Company, Inc.
21.3.14. Swedish Orphan Biovitrum AB
21.3.15. Takeda Pharmaceutical Company Limited
21.3.16. Teva Pharmaceutical Industries Ltd.
21.3.17. VectivBio AG
21.3.18. Viatris Inc.
21.3.19. Zealand Pharma A/S
22. ResearchAI
23. ResearchStatistics
24. ResearchContacts
25. ResearchArticles
26. Appendix
List of Figures
FIGURE 1. SHORT BOWEL SYNDROME MARKET MULTI-CURRENCY
FIGURE 2. SHORT BOWEL SYNDROME MARKET MULTI-LANGUAGE
FIGURE 3. SHORT BOWEL SYNDROME MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUGS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUGS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT CARE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT CARE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 18. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY COMPLICATION MANAGEMENT, 2024 VS 2030 (%)
FIGURE 20. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY COMPLICATION MANAGEMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITION TYPE, 2024 VS 2030 (%)
FIGURE 22. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ASSOCIATED CONDITIONS, 2024 VS 2030 (%)
FIGURE 24. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ASSOCIATED CONDITIONS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INNOVATIONS AND RESEARCH, 2024 VS 2030 (%)
FIGURE 26. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INNOVATIONS AND RESEARCH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 30. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 34. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 35. SHORT BOWEL SYNDROME MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 36. SHORT BOWEL SYNDROME MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SHORT BOWEL SYNDROME MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADULT SHORT BOWEL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PEDIATRIC SHORT BOWEL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY MEDICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DIETARY MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY MEDICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY BOWEL LENGTHENING PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTESTINAL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2 ANALOG, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TEDUGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2 ANALOG, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT CARE, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CAREGIVER ASSISTANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOME PARENTERAL NUTRITION, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITAL CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INPATIENT NUTRITIONAL SUPPORT, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITAL CARE, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY NON-SURGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INNOVATIVE DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY NON-SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INNOVATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ROBOTIC SURGICAL PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY COMPLICATION MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DEHYDRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTESTINAL FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY MALABSORPTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITION TYPE, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL NUTRITION, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY STANDARD PARENTERAL NUTRITION, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TAILORED NUTRITIONAL FORMULAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ASSOCIATED CONDITIONS, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CHRONIC MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DIET MODIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY LONG-TERM SUPPLEMENTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CHRONIC MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY EXTENDED RECOVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTESTINAL REHABILITATION PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY EXTENDED RECOVERY, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INNOVATIONS AND RESEARCH, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CLINICAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ONGOING TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CLINICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY EMERGING THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY MEDICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2 ANALOG, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT CARE, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITAL CARE, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY NON-SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY COMPLICATION MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITION TYPE, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ASSOCIATED CONDITIONS, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY CHRONIC MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY EXTENDED RECOVERY, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY INNOVATIONS AND RESEARCH, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY CLINICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY MEDICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2 ANALOG, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT CARE, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITAL CARE, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY NON-SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY COMPLICATION MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITION TYPE, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY ASSOCIATED CONDITIONS, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY CHRONIC MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY EXTENDED RECOVERY, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY INNOVATIONS AND RESEARCH, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY CLINICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY MEDICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2 ANALOG, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT CARE, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITAL CARE, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY NON-SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY COMPLICATION MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITION TYPE, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY ASSOCIATED CONDITIONS, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY CHRONIC MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY EXTENDED RECOVERY, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY INNOVATIONS AND RESEARCH, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY CLINICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 142. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 143. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 144. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY MEDICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 145. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 146. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 147. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2 ANALOG, 2018-2030 (USD MILLION)
TABLE 148. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, 2018-2030 (USD MILLION)
TABLE 149. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT CARE, 2018-2030 (USD MILLION)
TABLE 150. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 151. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITAL CARE, 2018-2030 (USD MILLION)
TABLE 152. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 153. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 154. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY NON-SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 155. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 156. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY COMPLICATION MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 157. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITION TYPE, 2018-2030 (USD MILLION)
TABLE 158. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2030 (USD MILLION)
TABLE 159. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY ASSOCIATED CONDITIONS, 2018-2030 (USD MILLION)
TABLE 160. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY CHRONIC MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 161. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY EXTENDED RECOVERY, 2018-2030 (USD MILLION)
TABLE 162. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY INNOVATIONS AND RESEARCH, 2018-2030 (USD MILLION)
TABLE 163. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY CLINICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 164. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 165. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 166. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 167. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY MEDICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 168. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 169. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 170. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2 ANALOG, 2018-2030 (USD MILLION)
TABLE 171. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, 2018-2030 (USD MILLION)
TABLE 172. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT CARE, 2018-2030 (USD MILLION)
TABLE 173. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 174. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITAL CARE, 2018-2030 (USD MILLION)
TABLE 175. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 176. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 177. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY NON-SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 178. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 179. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY COMPLICATION MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 180. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITION TYPE, 2018-2030 (USD MILLION)
TABLE 181. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2030 (USD MILLION)
TABLE 182. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY ASSOCIATED CONDITIONS, 2018-2030 (USD MILLION)
TABLE 183. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY CHRONIC MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 184. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY EXTENDED RECOVERY, 2018-2030 (USD MILLION)
TABLE 185. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY INNOVATIONS AND RESEARCH, 2018-2030 (USD MILLION)
TABLE 186. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY CLINICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 187. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 188. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 189. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 190. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY MEDICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 191. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 192. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 193. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2 ANALOG, 2018-2030 (USD MILLION)
TABLE 194. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, 2018-2030 (USD MILLION)
TABLE 195. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT CARE, 2018-2030 (USD MILLION)
TABLE 196. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 197. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITAL CARE, 2018-2030 (USD MILLION)
TABLE 198. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 199. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 200. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY NON-SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 201. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 202. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY COMPLICATION MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 203. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITION TYPE, 2018-2030 (USD MILLION)
TABLE 204. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2030 (USD MILLION)
TABLE 205. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY ASSOCIATED CONDITIONS, 2018-2030 (USD MILLION)
TABLE 206. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY CHRONIC MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 207. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY EXTENDED RECOVERY, 2018-2030 (USD MILLION)
TABLE 208. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY INNOVATIONS AND RESEARCH, 2018-2030 (USD MILLION)
TABLE 209. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY CLINICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 210. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 211. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 212. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 213. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 214. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY MEDICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 215. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 216. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 217. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2 ANALOG, 2018-2030 (USD MILLION)
TABLE 218. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, 2018-2030 (USD MILLION)
TABLE 219. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT CARE, 2018-2030 (USD MILLION)
TABLE 220. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 221. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITAL CARE, 2018-2030 (USD MILLION)
TABLE 222. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 223. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 224. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY NON-SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 225. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 226. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY COMPLICATION MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 227. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITION TYPE, 2018-2030 (USD MILLION)
TABLE 228. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2030 (USD MILLION)
TABLE 229. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY ASSOCIATED CONDITIONS, 2018-2030 (USD MILLION)
TABLE 230. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY CHRONIC MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY EXTENDED RECOVERY, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY INNOVATIONS AND RESEARCH, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY CLINICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 236. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 237. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 238. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY MEDICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 239. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 240. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 241. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2 ANALOG, 2018-2030 (USD MILLION)
TABLE 242. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, 2018-2030 (USD MILLION)
TABLE 243. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT CARE, 2018-2030 (USD MILLION)
TABLE 244. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 245. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITAL CARE, 2018-2030 (USD MILLION)
TABLE 246. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 247. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 248. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY NON-SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 249. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 250. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY COMPLICATION MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 251. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITION TYPE, 2018-2030 (USD MILLION)
TABLE 252. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2030 (USD MILLION)
TABLE 253. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY ASSOCIATED CONDITIONS, 2018-2030 (USD MILLION)
TABLE 254. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY CHRONIC MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 255. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY EXTENDED RECOVERY, 2018-2030 (USD MILLION)
TABLE 256. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY INNOVATIONS AND RESEARCH, 2018-2030 (USD MILLION)
TABLE 257. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY CLINICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 258. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 259. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 260. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 261. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY MEDICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 262. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 263. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 264. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2 ANALOG, 2018-2030 (USD MILLION)
TABLE 265. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, 2018-2030 (USD MILLION)
TABLE 266. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT CARE, 2018-2030 (USD MILLION)
TABLE 267. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 268. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITAL CARE, 2018-2030 (USD MILLION)
TABLE 269. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 270. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 271. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY NON-SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 272. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 273. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY COMPLICATION MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 274. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITION TYPE, 2018-2030 (USD MILLION)
TABLE 275. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2030 (USD MILLION)
TABLE 276. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY ASSOCIATED CONDITIONS, 2018-2030 (USD MILLION)
TABLE 277. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY CHRONIC MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 278. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY EXTENDED RECOVERY, 2018-2030 (USD MILLION)
TABLE 279. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY INNOVATIONS AND RESEARCH, 2018-2030 (USD MILLION)
TABLE 280. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY CLINICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 281. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 282. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 283. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 284. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY MEDICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 285. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 286. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 287. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2 ANALOG, 2018-2030 (USD MILLION)
TABLE 288. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, 2018-2030 (USD MILLION)
TABLE 289. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT CARE, 2018-2030 (USD MILLION)
TABLE 290. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 291. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITAL CARE, 2018-2030 (USD MILLION)
TABLE 292. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 293. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 294. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY NON-SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 295. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 296. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY COMPLICATION MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 297. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITION TYPE, 2018-2030 (USD MILLION)
TABLE 298. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2030 (USD MILLION)
TABLE 299. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY ASSOCIATED CONDITIONS, 2018-2030 (USD MILLION)
TABLE 300. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY CHRONIC MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 301. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY EXTENDED RECOVERY, 2018-2030 (USD MILLION)
TABLE 302. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY INNOVATIONS AND RESEARCH, 2018-2030 (USD MILLION)
TABLE 303. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY CLINICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 304. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 305. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 306. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 307. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY MEDICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 308. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 309. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 310. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2 ANALOG, 2018-2030 (USD MILLION)
TABLE 311. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, 2018-2030 (USD MILLION)
TABLE 312. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT CARE, 2018-2030 (USD MILLION)
TABLE 313. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 314. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITAL CARE, 2018-2030 (USD MILLION)
TABLE 315. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 317. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY NON-SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 318. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 319. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY COMPLICATION MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 320. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITION TYPE, 2018-2030 (USD MILLION)
TABLE 321. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2030 (USD MILLION)
TABLE 322. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY ASSOCIATED CONDITIONS, 2018-2030 (USD MILLION)
TABLE 323. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY CHRONIC MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 324. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY EXTENDED RECOVERY, 2018-2030 (USD MILLION)
TABLE 325. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY INNOVATIONS AND RESEARCH, 2018-2030 (USD MILLION)
TABLE 326. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY CLINICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 327. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 328. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 329. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 330. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY MEDICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 331. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 332. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 333. JAPAN SHORT BOWEL SYNDROME M

Companies Mentioned

  • 9 Meters Biopharma, Inc.
  • Adocia SAS
  • Ardelyx Inc.
  • AstraZeneca PLC
  • Emmaus Life Sciences, Inc.
  • Merck KGaA
  • Nestlé S.A.
  • Novartis International AG
  • OPKO Health, Inc.
  • Oxthera AB
  • Pfizer Inc.
  • PhaseBio Pharmaceuticals Inc.
  • Sancilio and Company, Inc.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • VectivBio AG
  • Viatris Inc.
  • Zealand Pharma A/S

Methodology

Loading
LOADING...

Related Topics

Related Reports

Short Bowel Syndrome Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Short Bowel Syndrome Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Short Bowel Syndrome (SBS) - Global Strategic Business Report - Product Image

Short Bowel Syndrome (SBS) - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Irritable Bowel Syndrome Treatment Market Size, Share & Analysis Report by Type (IBS-C, IBS-D), Product (Xifaxan, Linzess/Constella, Viberzi, Amitiza), Distribution Channel, Region, and Segment Forecasts, 2025-2030 - Product Image

Irritable Bowel Syndrome Treatment Market Size, Share & Analysis Report by Type (IBS-C, IBS-D), Product (Xifaxan, Linzess/Constella, Viberzi, Amitiza), Distribution Channel, Region, and Segment Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Irritable Bowel Syndrome (IBS) - Market Insight, Epidemiology, and Market Forecast - 2034 - Product Image

Irritable Bowel Syndrome (IBS) - Market Insight, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Short Bowel Syndrome - Pipeline Insight, 2025 - Product Image

Short Bowel Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • 80 Pages
  • Global
From

About the Short Bowel Syndrome Drug Market

Short Bowel Syndrome (SBS) is a rare disorder that affects the small intestine, resulting in malabsorption of nutrients and fluids. It is typically caused by the surgical removal of a large portion of the small intestine, or by a congenital defect. Treatment for SBS typically involves the use of specialized drugs to help the body absorb nutrients and fluids, as well as to reduce the risk of infection. The SBS drug market is a subset of the larger gastrointestinal drug market, which includes drugs used to treat a variety of gastrointestinal disorders. The SBS drug market is relatively small, but is expected to grow in the coming years due to increasing awareness of the disorder and the development of new treatments. Some of the major companies in the SBS drug market include AbbVie, Allergan, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Takeda. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.